Manage Your Liver
Q:

WHO’s latest Hepatitis strategies are focused on preventing and reducing damage caused by hepatitis, what should hepatitis B and C patients do?

A:

According to the latest data provided by the World Health Organization, there are 400 million people living with hepatitis B and C worldwide; 1.4 million die due to these infections every year and many more become newly infected. [1] In recent years, WHO launched a range of new strategies and guidelines for this serious global problem. In 2014 and 2015, for the first time, WHO introduced countermeasures guidance to countries around the world on hepatitis C and B respectively. In the guidelines, WHO clearly presented a 3-part prevention plan which included (not limited to) the following [2]:

 

  • immunization with the hepatitis A and B vaccines to prevent co-infection from these hepatitis viruses to protect the liver;
  • early and appropriate medical management including antiviral therapy if appropriate; and
  • regular monitoring for early diagnosis of chronic liver disease (including liver cirrhosis and liver cancer)

 

Another document published by WHO – “Prevention and Control of Viral Hepatitis Infection” further states that our goals should be to reduce morbidity and mortality due to viral hepatitis, improve the care of patients with viral hepatitis and improve the support provided by our society to hepatitis patients. [3] This implies that WHO is recommending hepatitis patients to think further; other than just killing the virus, focus should also be put on these aspects: how to avoid the spread of the virus, how to reduce liver damage caused by the virus, how to prevent liver cirrhosis and liver cancer, and how to improve activity and ability to work.

 

In a sense, it also shows that WHO does not consider the effects of current treatment options on viral hepatitis B and C to be ideal. These treatments advocated by various professionals failed to address the hazards of viral hepatitis B and C, prevent new infections, and lower the number of patients, or the number of deaths caused by the disease. However, countries around the world have paid a very high price because of these ineffective methods.

 

For now, the general consensus is that our focus should be put on: preventing new infections and reducing the spread of the virus, advocating and seeking ways to reduce inflammation and damage caused by hepatitis, preventing inflammation in the liver to reduce risks of liver cirrhosis and liver cancer, and improving the everyday ability and life skills of hepatitis patients.

 

In this context, our liver health maintenance methods that we advocate and promote are very much in line with the proposal and conclusions by WHO.

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Tags:
Hepatitis BHepatitis CViral Hepatitis Hep BHep C WHO
Related Questions
A:
ALT (Alanine Aminotransferase / SGPT) is an enzyme that is mainly found in liver cells. The level of ALT in our bloodstream is the primary indicator of liver health. Multiple studies have demonstrated that the presence of an elevated ALT level is associated with increased liver-related mortality.   New normal ALT level issued The American College of Gastroenterology (ACG) recently issued a new Practice Guideline that aims to offer a framewor
A:
ALT (Alanine Aminotransferase / SGPT) is an enzyme that is mainly found in liver cells. The level of ALT in our bloodstream is the primary indicator of liver health.   What does high ALT indicate? ALT enzymes are normally contained within liver cells when the liver is healthy, but when the liver cells are injured or damaged by whatever means, ALT enzymes are released into the bloodstream, causing levels to go up. Therefore, by measuring the
Hit Questions
A:
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common liver diseases. They occur in people who drink little or no alcohol at all and are considered to be consequences of obesity.    However, “not obese” does not equal “no NAFLD / NASH”, since NAFLD may not be linked with obesity in some cases. Fatty liver disease may also develop in non-obese people. The terms “lean NAFLD” and “lean
A:
With thousands of supplements in the market, and little regulations on supplements, finding a suitable one is difficult enough, let alone finding a SAFE one!   Here we will look at 5 things that you can look for when buying or using supplements, it can help you to avoid risky products and limited the chance of using something unsafe:   1. Look for registrations In some country, there are registration systems on suppl
A:
There are various different causes of liver disease; one of these is excessive alcohol drinking which causes ‘alcoholic liver disease’. Alcohol-related liver disease is currently the most prevalent cause of advances liver diseases in Europe. [1]   What does alcohol do to your liver? It’s obvious that drinking too much alcohol can damage your liver but the exact reason behind is uncertain. However, scientists believe this is
A:
ALT (Alanine Aminotransferase / SGPT) is a type of enzyme found in liver cells. When the liver cells are functioning normally, the ALT enzymes should be contained within the liver cells.    You can imagine each liver cells as a balloon, and the ALT enzymes are the air inside the balloon. When the balloon is damaged, the air will be released. And when the liver cells is damaged, ALT enzymes are released into the bloodstream, therefore we are able to find out the l
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Looking for help? Ask our customer support team!
Contact Us